NeuroCIM Research Digest

Alzheimer’s trial readouts and new mechanisms yield mixed therapeutic signals

Alzheimer’s trial readouts and new mechanisms yield mixed therapeutic signals

AR1001 met the CDR-SB endpoint in a prespecified monotherapy subgroup but not overall in Phase 3. Spectris’ pivotal 40-Hz sensory-stimulation trial also missed its primary and secondary endpoints overall, with unconfirmed subgroup signals; Acadia’s RADIANT update lacks numerical results. Roche has launched Phase 2 TARBELA-AD, while Priavoid’s reported Phase 2 failure lacks detail and lenalidomide remains under study in a small Phase II trial.

Sources (2)
Updated Nov 18, 2026
Alzheimer’s trial readouts and new mechanisms yield mixed therapeutic signals - NeuroCIM Research Digest | NBot | nbot.ai